Peer Review

Jackie Fouse gets back into biopharma as executive chairman of Dermavant; Ex-GSK chief Andrew Witty joins a biotech board

Jackie Fouse

→ A little more than four months after Jackie Fouse said she was “retiring” as president of Celgene, she’s back running her own biotech as executive chairman of Dermavant, one of several new “vants” that Roivant chief Vivek Ramaswamy has kicked into play over the last three years.

Tony Wood, Pfizer’s senior vice president of medicinal sciences, has been wooed over to take a key R&D posting at the UK pharma giant. And the move includes a shift in assignments tied to a new effort at GSK involving the use of artificial intelligence in drug development. John Baldoni, who previously led this effort, is moving to head up a new team focused on “enhancing drug discovery through the use of in silico technology — including artificial intelligence, machine learning and deep learning.”

Andrew Witty is joining the board of directors at Research Triangle Park, NC-based G1 Therapeutics. The move comes just a few months after Witty’s retirement from the helm at GSK.

Amy Chevalier Efantis will take over as vice president of government affairs for Biogen. She’ll be based in Washington, DC and formerly worked at Boehringer.

Srinivas G. Rao is resigning from his position as chief medical officer at Depomed. He took a lump cash payment in connection with his termination, according to an SEC filing.

→ Verastem announced the appointment of Julie B. Feder as Chief Financial Officer.

Aeglea BioTherapeutics has named James Wooldridge as its new chief medical officer. Wooldridge is an Eli Lilly veteran, where he held several titles.

Provention Bio tapped Eleanor “Leni” Ramos for the role of chief medical and chief operating officer.

 


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biomanufacturing